Oral BPC-157 bioavailability claims: what the data actually shows

What did @extraleonardo actually say?

The creator argues that oral BPC-157 is a waste of money for anyone hoping to heal injuries outside the gut. His core claim: bioavailability of swallowed BPC-157 is under 5%, that absorbed fraction only affects gut tissue, and that BPC-157 is a "localized peptide" that must be injected near the injury site to trigger angiogenesis and reduce inflammation. He also says he's been advising against oral versions since 2020 and invites followers to DM him directly.

That last part, the DM pitch, is worth flagging upfront. It's a common funnel for peptide sales. That doesn't automatically make his claims wrong, but it's context worth holding onto as you read the science.

Does the science back this up?

Partially, but not as cleanly as he presents it. The bioavailability concern is real and the localized-action argument has support, but the picture is more complicated than "oral does nothing."

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Animal studies, mostly rodent models, have shown it accelerates healing of tendons, muscles, and even brain tissue when injected. The angiogenesis mechanism he describes is real. BPC-157 appears to upregulate VEGFR2 signaling and promote nitric oxide release, both of which drive new blood vessel formation. That part checks out.

On oral bioavailability, a commonly cited figure in peptide research is that most unprotected peptides are degraded in the GI tract before meaningful systemic absorption occurs. Chang et al. (2011, Journal of Physiology-Paris) and subsequent animal studies did show orally administered BPC-157 produced effects in gut models, which supports his point that oral dosing may have GI-specific utility. However, some animal studies have also shown systemic effects from oral BPC-157, including muscle and tendon outcomes, though these used doses far exceeding anything a human would typically take.

What did they get wrong (or right)?

He got the general direction right but overstated the certainty of several points.

Saying BPC-157 is strictly "not systemic" is an oversimplification. It's more accurate to say systemic bioavailability via oral route is low and inconsistent, not zero. Some animal data does show peripheral effects after oral administration. The mechanism isn't fully understood, and extrapolating rodent pharmacokinetics to humans is a significant leap regardless of route.

The specific "less than 5%" figure he cites lacks a clear published source for humans. That number circulates widely in peptide communities but robust human pharmacokinetic data for BPC-157 essentially does not exist, because no form of BPC-157 has completed phase III clinical trials. We are working from animal studies and anecdote, full stop.

His claim that injected BPC-157 must go "closest to the injury site" reflects a reasonable clinical rationale, but it's not definitively proven that subcutaneous injection distant from the injury fails. Some practitioners use systemic subcutaneous injections with reported success. The localized injection protocol is a hypothesis with supporting logic, not established medical consensus.

Where he's on solid ground: oral BPC-157 for systemic musculoskeletal healing is not well-supported by evidence, and promoting it aggressively as equivalent to injectable forms is misleading to consumers.

What should you actually know?

BPC-157 in any form, oral or injectable, is not FDA-approved. It is not a licensed drug. The evidence base is almost entirely preclinical, meaning animal studies, and human trials are limited, small, and not peer-reviewed at a level that meets regulatory standards. The FDA placed BPC-157 on a list of substances that cannot be used in compounded medications in 2022, citing insufficient evidence of safety and efficacy.

If someone is selling you oral BPC-157 as a healing supplement, or injectable BPC-157 through a telehealth platform without a proper clinical evaluation, those are red flags worth taking seriously. The creator's core warning that oral BPC-157 is unlikely to heal a knee or shoulder the way injectable might is grounded in reasonable pharmacology, but neither route has been validated in rigorous human trials.

Anyone considering peptide therapy should speak with a licensed clinician who can review their full health history, not take cues from a TikTok video, including this one, or a DM from a social media account.

Bottom line on the creator's credibility here

@extraleonardo makes claims that align with prevailing peptide community thinking, and some of that thinking is backed by animal data. But he presents contested pharmacokinetic figures as settled fact, overstates the "localized" nature of BPC-157 action, and ends with a DM pitch that suggests a commercial interest. Credit where it's due: warning people away from hyped oral peptide products is a reasonable position. But the confidence level in this video exceeds what the actual evidence supports.